For many years, it was believed that when an individual develops liver scarring, it can not be reversed. Today, we know that ...

Chimeric antigen receptor, or CAR, therapy is no longer just a cancer story. This review shows how the field is expanding beyond conventional CAR-T cells into a wider family of engineered cell ...

Inside the deadly disease confounding medicine, researchers piecing together clues and the breakthrough that meant survival ...

The text messages motivate Christian Collins to keep inspiring others. One told the USC-bound forward about three family ...

A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers ...

The patient in the current case report showed manifestations of both AAV and IgG4-RD; his improvement linked to steroid/cyclophosphamide treatment underscores the need for integrated diagnosis and ...

The investigators explained that GLP-1 receptor agonists appear to be able to help resolve MASH without worsening fibrosis. Those findings have been confirmed in mouse models and in multiple studies ...

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...

A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers ...

Co. Ltd. has patented new 2-phenyl-1,2,4-triazine-3,5(2h,4h)-dione derivatives acting as thyroid hormone receptor β (THR-β) agonists potentially useful for the treatment of diabetes, obesity, ...

Cancer therapeutics and orphan drugs are no longer niche areas. Specialty drugs are now a significant portion of the ...

Morgan Stanley, Leerink Partners, Cantor, and Stifel are acting as joint book-running managers for the offering and Oppenheimer & Co. is acting as lead manager. The offering is subject to market and ...